Trial intelligence / Profile preview

LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis

2024-512676-36-00Phase 3Authorised

Sponsor: St. Anna Children's Cancer Research Institute
Start: Oct 2024
Modality: Small Molecules
Countries: 23

Overview

Phase 3 trial of cladribine in Langerhans cell histiocytosis (LCH), sponsored by St. Anna Children's Cancer Research Institute. Primary endpoints: Reactivation-free survival, Overall survival and 4 more. Planned start Oct 2024; status: authorised.

Drugs

cladribine

Conditions

Langerhans cell histiocytosis (LCH)

Beyond the preview

Go deeper on 2024-512676-36-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-512676-36-00.